Clinical trial
Open access
Sep 2026
AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer
Ociperlimab and tislelizumab±chemotherapy demonstrated a manageable safety profile and preliminary antitumor activity in patients with NSCLC or ES-SCLC and should be interpreted with caution.
Shun Lu, Yan Yu, Jun Zhang et al.
· Journal for ImmunoTherapy of... · 0 citations